Clear Search

Showing 8 results for “Glucocorticoids”.

March 2024
September 2023

Preclinical Evidence for the Glucocorticoid-Sparing Potential of a Dual Toll-Like Receptor 7/8 Inhibitor in Autoimmune Diseases

J Pharmacol Exp Ther. 2023 doi: 10.1124/jpet.123.001744 Epub ahead of print

Preclinical evidence indicates a glucocorticoid (GC)-sparing potential for toll-like receptor (TLR)7/8 inhibitor compounds, suggesting TLR7/8i may offer a new strategy for the treatment of autoimmune diseases.

more…

August 2023

Effect of Belimumab on Kidney-related Outcomes in Patients with Lupus Nephritis: Post Hoc Subgroup Analyses of the Phase 3 BLISS-LN Trial

Nephrol Dial Transplant. 2023;38(12):2733–42 doi: 10.1093/ndt/gfad167 Epub ahead of print.

These data highlight the consistent benefit of belimumab versus placebo, combined with standard therapy, on kidney outcomes in both newly diagnosed and relapsed patients, and regardless of the use of GC pulses at induction.

more…

July 2023

Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis

Arthritis Care Res (Hoboken). 2023 Jul;75(7):1399–1408 DOI: 10.1002/acr.25007

Pooled analysis of data from the AURA-LV phase 2 and AURORA 1 phase 3 trials of voclosporin in patients with active LN demonstrated that significantly more patients achieved a complete renal response at 1 year in the voclosporin than the control group (p<0.0001), with no observation of new safety signals.

more…

February 2023

Lupus Low Disease Activity State Attainment in the Phase 3 TULIP Trials of Anifrolumab in Active Systemic Lupus Erythematosus

Ann Rheum Dis. 2023. doi: 10.1136/ard-2022-222748

Post-hoc anaylsis of TULIP trials shows that, compared with placebo, anifrolumab treatment was associated with earlier, more frequent, and more prolonged and sustained lupus low disease activity state (LLDAS).

more…

July 2022
March 2022